🇺🇸 FDA
Patent

US 9839685

Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen

granted A61KA61K2039/541A61K2039/543

Quick answer

US patent 9839685 (Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/541, A61K2039/543, A61K2039/55555, A61K2039/55561